Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135718 · ClinicalTrials.gov registry record
ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 288
- Enrollment target
NCT02135718 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 288 participants.
The verdict
NCT02135718 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 288 participants
- Enrollment target
Study Summary
This is a multicenter, stratified, and randomized, open-label, placebo study in subjects with asthma to compare inhalers, ELLIPTA a new dry powder inhaler (DPI) and metered dose inhalers (MDI). This study is conducted to evaluate subject's preference of several inhaler-specific attributes individually between an existing MDI and the ELLIPTA a dry powder inhaler. Subjects who have not used the ELLIPTA inhaler in the past 6 months and their asthma must be controlled on their current therapy were enrolled. Subjects meeting the eligibility criteria will be stratified according to their current inhaler use (stable for the past 3 months): 1.) Currently using a DPI as an inhaled asthma controller therapy OR 2.) Currently using an MDI as an inhaled asthma controller therapy (No fluticasone MDI use in the last 3 months) OR 3.) Currently using no inhaled asthma controller therapy (this includes patients using a LTM and/or SABA only). Once stratified, eligible subjects were randomized (1:1) to one of two sequences for using the inhaler: ELLIPTA inhaler once daily in Period 1 followed by MDI twice daily in Period 2 or MDI twice daily in Period 1 followed by ELLIPTA inhaler once daily in Period 2 for for 5-9 days each. In addition, subjects will be randomly assigned (1:1 allocation) to receive one of two sets of questions: Version 1 presents response options in the order of ELLIPTA inhaler, MDI, No preference; Version 2 presents response options in the order of MDI, ELLIPTA inhaler, No preference. At the end of the second trial period, subjects answered questions which assessed their preference of inhaler attributes. ELLIPTA is a registered trademark of the GSK group of companies.
Interventions
- DEVICE ELLIPTA inhaler
- DEVICE Placebo Inhalation Aerosol (MDI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02135718
The ClinicalTrials.gov registry entry for NCT02135718 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ELLIPTA inhaler is the first listed.
NCT02135718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02135718 about?
NCT02135718 is a clinical study titled "ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma". This is a multicenter, stratified, and randomized, open-label, placebo study in subjects with asthma to compare inhalers, ELLIPTA a new dry powder inhaler (DPI) and metered dose inhalers (MDI). This study is conducted to evaluate subject's preference of several inhaler-specific attributes individual...
What is the current status of trial NCT02135718?
This trial is currently completed. The enrollment target is 288 participants. The study started on 2014-06. Estimated completion is 2014-07.
What interventions are being tested in trial NCT02135718?
The interventions under investigation include: ELLIPTA inhaler (DEVICE), Placebo Inhalation Aerosol (MDI) (DEVICE).
Who is sponsoring clinical trial NCT02135718?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.